Evidence map›Paper›PMID 38515753›Full record

ArticleFrontiers in immunology2024

Effect of pancreas disease vaccines on infection levels and virus transmission in Atlantic salmon (

Ragnar Thorarinsson, Anne Ramstad, Jeffrey C Wolf, Hilde Sindre, Eystein Skjerve, Espen Rimstad, Øystein Evensen, Jose F Rodriguez

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Plasmid-DNA EncodedPharmaceutics · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Ragnar ThorarinssonElanco Animal Health, Bergen, Norway.
Anne RamstadVESO Aqualab, Vikan, Namsos, Norway.
Jeffrey C WolfExperimental Pathology Laboratories Inc., Sterling, VA, United States.
Hilde SindreNorwegian Veterinary Institute, Ås, Norway.
Eystein SkjerveFaculty of Veterinary Medicine, Norwegian University of Life Sciences, Ås, Norway.
Espen RimstadFaculty of Veterinary Medicine, Norwegian University of Life Sciences, Ås, Norway.
Øystein EvensenFaculty of Veterinary Medicine, Norwegian University of Life Sciences, Ås, Norway.
Jose F RodriguezElanco Canada Ltd., Mississauga, ON, Canada.
Norwegian University of Life Sciences · NOEllisDon (Canada) · CAExperimental Pathology Laboratories · USNorwegian Veterinary Centre for Contract Research and Commercial Services · NONorwegian Veterinary Institute · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salmonid alphavirus (SAV) causes pancreas disease (PD), which negatively impacts farmed Atlantic salmon. In this study, fish were vaccinated with a DNA-PD vaccine (DNA-PD) and an oil-adjuvanted, inactivated whole virus PD vaccine (Oil-PD). Controls were two non-PD vaccinated groups. Fish were kept in one tank and challenged by cohabitation with SAV genotype 2 in seawater. Protection against infection and mortality was assessed for 84 days (Efficacy study). Nineteen days post challenge (dpc), subgroups of fish from all treatment groups were transferred to separate tanks and cohabited with naïve fish (Transmission study 1) or fish vaccinated with a homologous vaccine (Transmission study 2), to evaluate virus transmission for 26 days (47 dpc). Viremia, heart RT-qPCR and histopathological scoring of key organs affected by PD were used to measure infection levels. RT-droplet digital PCR quantified shedding of SAV into water for transmission studies. The Efficacy study showed that PD associated growth-loss was significantly lower and clearance of SAV2 RNA significantly higher in the PD-DNA group compared to the other groups. The PD-DNA group had milder lesions in the heart and muscle. Cumulative mortality post challenge was low and not different between groups, but the DNA-PD group had delayed time-to-death. In Transmission study 1, the lowest water levels of SAV RNA were measured in the tanks containing the DNA-PD group at 21 and 34 dpc. Despite this, and irrespective of the treatment group, SAV2 was effectively transmitted to the naïve fish during 26-day cohabitation. At 47 dpc, the SAV RNA concentrations in the water were lower in all tanks compared to 34 dpc. In Transmission study 2, none of the DNA-PD immunized cohabitants residing with DNA-PD-vaccinated, pre-challenged fish got infected. In contrast, Oil-PD immunized cohabitants residing with Oil-PD-vaccinated, pre-challenged fish, showed infection levels similar to the naïve cohabitants in Transmission study 1. The results demonstrate that the DNA-PD vaccine may curb the spread of SAV infection as the DNA-PD vaccinated, SAV2 exposed fish, did not spread the infection to cohabiting DNA-PD vaccinated fish. This signifies that herd immunity may be achieved by the DNA-PD vaccine, a valuable tool to control the PD epizootic in farmed Atlantic salmon.

Indexed as

AlphavirusFish DiseasesPancreatic DiseasesSalmo salarVaccines, DNAViral VaccinesAnimalsDNAGenotypePancreasRNAWaterDNARNAVaccines, DNAViral VaccinesWaterAtlantic salmondisease transmissionDNA vaccinepancreas diseasesalmonid alphavirusvaccine efficacyviral shedding

Identifiers

PMID38515753
PMCPMC10955579
OpenAlexW4392553577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.